Research Study Summary
A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
To Learn more
CW ID: 222922
Date Last Changed:
February 3, 2017
Clinical Trial Snapshot
- Both Male and Female
- 45 to 80 Years
- Overall Status
- Facility Type
Females of non-childbearing potential and/or male subjects
Clinical diagnosis of Parkinson's disease.
Parkinson's Disease Hoehn & Yahr Stage I-III inclusive
Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days
Able to refrain from any Parkinson's disease medication not permitted by the protocol.
History or presence of atypical Parkinsonian syndrome.
Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality.
Any condition possibly affecting drug absorption.
Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.